HUF-101

HUF-101 is a synthetic cannabinoid that is part of the indazole-3-carboxamide family of cannabinoids. It is a potent agonist of the CB1 receptor, with a binding affinity of 0.0468 nM, making it one of the most potent cannabinoids known. HUF-101 was first synthesized by a team of researchers at the Hebrew University of Jerusalem in 2014.

Chemistry

HUF-101 is a synthetic cannabinoid, meaning it is not naturally occurring but is instead created in a laboratory. It is part of the indazole-3-carboxamide family of cannabinoids, which also includes compounds such as AB-FUBINACA and AB-PINACA. The chemical structure of HUF-101 is characterized by an indazole core, a 3-carboxamide moiety, and a 1-amino-3,3-dimethyl-1-oxobutan-2-yl (ADB) group.

Pharmacology

HUF-101 is a potent agonist of the CB1 receptor, with a binding affinity of 0.0468 nM. This makes it one of the most potent cannabinoids known. The CB1 receptor is one of the two main types of cannabinoid receptors in the body, the other being the CB2 receptor. These receptors are part of the endocannabinoid system, which plays a role in a variety of physiological processes including pain sensation, mood, and memory.

Synthesis

HUF-101 was first synthesized in 2014 by a team of researchers at the Hebrew University of Jerusalem. The synthesis process involves the reaction of the appropriate indazole-3-carboxamide with the ADB group in the presence of a suitable catalyst.

Legal Status

The legal status of HUF-101 varies by country. In some countries, it is classified as a controlled substance due to its similarity to other synthetic cannabinoids. In others, it is legal to possess and use for research purposes.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system

References

This article is a stub related to medicine. You can help WikiMD by expanding it!